DE

Dr. Richard Van Etten

Director of the Chao Family Comprehensive Cancer Center and a Professor of Medicine and Biological Chemistry at the University of California Irvine; physician in the Division of Hematology/Oncology at the University of California Irvine Medical Centre

Since 2020

1

cases · 1 yrs · FC

Trial

Motion

Costs

Appeal

Sentencing

1 total

WB

Patent claims for recombinant G-CSF declared invalid for obviousness.

Amgen brought a patent infringement action against Pfizer regarding a biologic drug, filgrastim.

Pfizer counterclaimed that the asserted claims of the patent were invalid for obviousness, material misrepresentation, and insufficiency.

The court found that the asserted claims were obvious to try as of the invention date in 1985, given the state of the art and the routine nature of the required work.

The court dismissed the allegations of material misrepresentation and insufficiency.

Amgen Inc. v. Pfizer Canada ULC, 2020 FC 522

Director of the Chao Family Comprehensive Cancer Center and a Professor of Medicine and Biological Chemistry at the University of California Irvine; physician in the Division of Hematology/Oncology at the University of California Irvine Medical Centre · hematology, protein biochemistry, and molecular biology, including recombinant DNA technology

DE

Intellectual Property Law

Dr. Richard Van Etten

Director of the Chao Family Comprehensive Cancer Center and a Professor of Medicine and Biological Chemistry at the University of California Irvine; physician in the Division of Hematology/Oncology at the University of California Irvine Medical Centre

Since 2020

1

cases · 1 yrs · FC

Trial

Motion

Costs

Appeal

Sentencing

1 total

WB

William A. Bortolin

In Private Practice15 cases2015–2026

PJ

Paul Jorgensen

2 cases2020–2021

OP

Orestes Pasparakis

In Private Practice51 cases2003–2026

MD

Mark Davis

2 cases2020–2021

KS

Kassandra Shortt

In Private Practice4 cases2020–2024

EK

Emily P. Kettel

1 case2020–2020

DH

Dominique T. Hussey

1 case2020–2020

DD

Dan Daniele

1 case2020–2020

AR

Arthur B. Renaud

Not Practising Law2 cases2004–2020

RS

Richard F. Southcott

FC69 cases2020–2024

FCApr 16, 2020

Patent claims for recombinant G-CSF declared invalid for obviousness.

Amgen brought a patent infringement action against Pfizer regarding a biologic drug, filgrastim.

Pfizer counterclaimed that the asserted claims of the patent were invalid for obviousness, material misrepresentation, and insufficiency.

The court found that the asserted claims were obvious to try as of the invention date in 1985, given the state of the art and the routine nature of the required work.

The court dismissed the allegations of material misrepresentation and insufficiency.

Amgen Inc. v. Pfizer Canada ULC, 2020 FC 522

Director of the Chao Family Comprehensive Cancer Center and a Professor of Medicine and Biological Chemistry at the University of California Irvine; physician in the Division of Hematology/Oncology at the University of California Irvine Medical Centre · hematology, protein biochemistry, and molecular biology, including recombinant DNA technology